O ften seen as a rite of passage, acne is nonetheless an unwelcome skin affliction with damaging psychosocial effects, even in its mildest form. Now evidence suggests that children may start to contend with this skin disease sooner in life.
Although acne typically presents in puberty with a prevalence of 70 to 80% of teenagers, 1 it is increasingly common for acne to be seen in children younger than age 12. 2, 3 Goldberg and colleagues observed a significant decrease in the mean age of children seeking treatment for acne after analyzing national patient data about physician visits for acne in children ages 6 to 18 years over a 28-year time span . 2 The dramatic drop in the average age of new acne patients may reflect an earlier onset of puberty.
As we know, acne can appear throughout life, from infancy through adulthood. Regardless of when it appears, it may require treatment, and if so, acne should be treated early and appropriately. What has been unclear to date is how to treat it best in children. Aiming to remedy this are the first detailed, evidence-based guidelines for the management of pediatric acne developed by the American Acne and Rosacea Society and endorsed by the American Academy of Pediatrics. The new guidelines appeared recently in the May 2013 issue of the journal Pediatrics. 4 The consensus recommendations are the result of a major literature search categorized into 10 major topic areas and reviewed by an expert panel composed of pediatric dermatologists, pediatricians, and dermatologists with an expertise in acne.
The new guidelines are significant as far as providing a cohesive approach to the management of pediatric acne across various medical specialties. The treatment of acne in the pediatric population has been challenging given the scarcity of studies that assessed the safety and efficacy of acne treatments in patients less than 12 years of age. These gaps in knowledge have resulted in off-label prescribing, leaving the choice of treatment largely to the discretion of the individual physician. 5 The trouble is that physicians are not always on the same page. A study that examined prescribing patterns between dermatologists and primary care physicians found a major difference between the medical specialties: dermatologists tended to prescribe topical retinoids for these younger acne patients, whereas general practitioners (GPs) prescribed oral antibiotics preferentially. 5 In an earlier US-based study, Yentzer and colleagues showed that dermatologists prescribed topical retinoids for acne almost four times as often as pediatricians (46.1% vs 12.1%). 6 To complicate matters, GPs are much less likely to properly recognize acne morphology compared to dermatologists. 7 It is hoped that if these new guidelines are used appropriately by those dealing with young acne patients, we will begin to see a reduction in the number of patients being referred to dermatologists after ''failed'' treatment. This point is highlighted in the guideline report: lack of adherence is a major determinant of treatment failure. The expert panel suggested that if a treatment seemed ineffective, the initial steps would be to verify that the patient is using the acne treatment as prescribed and to reinforce proper product use through reeducation. In cases of a true ''inadequate response,'' then modification of the treatment plan would be indicated.
In large part, the treatment advice for preadolescent acne patients reflects what we recommend for adolescents, even though the recommendations for these younger patients are based primarily on expert opinion. The guidelines also suggest the need to consider underlying causes of acne in some cases. For example, although acne between 1 and 7 years of age is rare, children presenting with acne at this stage should, in some cases, be considered for a referral to a pediatric endocrinologist for adrenal or gonadal/ovarian assessment.
Many of the recommendations mirror current dermatology practice: Given that pediatric acne is becoming an increasingly common issue, guidelines that aim to unify therapeutic efforts across specialties are welcome. For dermatologists, these recommendations should help to improve patient outcomes and lighten our load in the context of not seeing patients who could otherwise be managed by our nondermatology colleagues.
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